Gout is a type of arthritis caused by high uric acid levels in the body. Uric acid is a result of purine metabolism in the body and causes uric acid crystals to form which are hard and painful to pass. Gout is one of the most commonly diagnosed joint diseases around the world. Gout patients experience redness, swelling, stiffness, and joint inflammation. The drug discovery pipeline is mainly focused on four main areas of Asia gout disease treatment including rheumatoid arthritis, tendonitis, osteonecrosis, and uric acid metabolism. Gout disease is caused by the accumulation of uric acid crystals in the joints.
The primary focus of the Asia gout disease treatment market is on the research to determine how to treat monoclonal antibodies (anti-Gout proteins). Monoclonal antibodies can be either naturally produced by the human body or can be produced artificially, with the advent of novel transgenic plants. The first such transgenic plant was introduced in 1990, and since then there have been further introductions of new crops. The transgenic plants are designed to produce antibodies in a way that they target the uric acid-producing factor (UGA) protein. These plants, therefore, are capable of producing the antibodies to attack Gout protein in patients with Gout and so are likely to succeed in bringing about a cure for Gout.
Most medications used for gout disease work by reducing the ability of the body to dispose of uric acid through urine. They reduce the amount of uric acid that is manufactured and excreted through the kidneys, but they do not stop the formation of urate crystals in the first place. Generally, they are only effective for relieving the immediate symptoms of gout such as swelling, redness, and joint stiffness. As an alternative, you may want to consider taking over-the-counter medications for the symptoms of gout disease that do not relieve the swelling or pain in your joints.
No comments:
Post a Comment